EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study

Sarah E Turbett iD, Christopher H Tomkins-Tinch, Melis N Anahtar, Caitlin M Dugdale, Emily P Hyle, Erica S Shenoy, Bennett Shaw, Kenechukwu Egbuonu, Kathryn A Bowman, Kimon C Zachary, Gordon C Adams, David C Hooper und 11 weitere

Clinical Infectious Diseases · 04.03.2023 · 76 (5) · 850-860

DOI: 10.1093/cid/ciac830 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.10.2022. Verfasst von Sarah E Turbett und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Howard Hughes Medical Institute, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection is poorly understood, partly because few studies have systematically applied genomic analysis to distinguish reinfection from persistent RNA detection related to initial infection. We aimed to evaluate the characteristics of SARS-CoV-2 reinfection and persistent RNA detection using independent genomic, clinical, and laboratory assessments.

Methods

All individuals at a large academic medical center who underwent a SARS-CoV-2 nucleic acid amplification test (NAAT) ≥45 days after an initial positive test, with both tests between 14 March and 30 December 2020, were analyzed for potential reinfection. Inclusion criteria required having ≥2 positive NAATs collected ≥45 days apart with a cycle threshold (Ct) value <35 at repeat testing. For each included subject, likelihood of reinfection was assessed by viral genomic analysis of all available specimens with a Ct value <35, structured Ct trajectory criteria, and case-by-case review by infectious diseases physicians.

Results

Among 1569 individuals with repeat SARS-CoV-2 testing ≥45 days after an initial positive NAAT, 65 (4%) met cohort inclusion criteria. Viral genomic analysis characterized mutations present and was successful for 14/65 (22%) subjects. Six subjects had genomically supported reinfection, and 8 subjects had genomically supported persistent RNA detection. Compared to viral genomic analysis, clinical and laboratory assessments correctly distinguished reinfection from persistent RNA detection in 12/14 (86%) subjects but missed 2/6 (33%) genomically supported reinfections.

Conclusions

Despite good overall concordance with viral genomic analysis, clinical and Ct value-based assessments failed to identify 33% of genomically supported reinfections. Scaling-up genomic analysis for clinical use would improve detection of SARS-CoV-2 reinfections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansCOVID-19 TestingReinfectionRetrospective StudiesSARS-CoV-2RNA

Stichwörter der Autor:innen

COVID-19SARS-CoV-2 reinfectionpersistent detection

Substanzen

RNA

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
  • Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, USA.
  • Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.
  • Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Sarah E Turbett

Förderung

  • NIAID NIH HHS
  • Howard Hughes Medical Institute
  • NHLBI NIH HHS
  • NCI NIH HHS
  • NCEZID CDC HHS
  • CDC HHS
  • NIA NIH HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Turbett, S. E., Tomkins-Tinch, C. H., Anahtar, M. N., Dugdale, C. M., Hyle, E. P., Shenoy, E. S., Shaw, B., Egbuonu, K., Bowman, K. A., Zachary, K. C., Adams, G. C., Hooper, D. C., Ryan, E. T., LaRocque, R. C., Bassett, I. V., Triant, V. A., Siddle, K. J., Rosenberg, E., Sabeti, P. C., …, & Charles, R. C. (2023). Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study. Clinical Infectious Diseases, 76(5), 850-860. https://doi.org/10.1093/cid/ciac830

Vancouver

Turbett SE, Tomkins-Tinch CH, Anahtar MN, Dugdale CM, Hyle EP, Shenoy ES, et al. Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study. Clinical Infectious Diseases. 2023;76(5):850-860. doi:10.1093/cid/ciac830

BibTeX
@article{Turbett2023,
  author = {Turbett, Sarah E and Tomkins-Tinch, Christopher H and Anahtar, Melis N and Dugdale, Caitlin M and Hyle, Emily P and Shenoy, Erica S and Shaw, Bennett and Egbuonu, Kenechukwu and Bowman, Kathryn A and Zachary, Kimon C and Adams, Gordon C and Hooper, David C and Ryan, Edward T and LaRocque, Regina C and Bassett, Ingrid V and Triant, Virginia A and Siddle, Katherine J and Rosenberg, Eric and Sabeti, Pardis C and Schaffner, Stephen F and MacInnis, Bronwyn L and Lemieux, Jacob E and Charles, Richelle C},
  title = {Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {5},
  pages = {850--860},
  doi = {10.1093/cid/ciac830}
}
Kostenlos starten →